News for 'Sun Pharmaceuticals'

Data leak shows massive infiltration by China's Communist Party

Data leak shows massive infiltration by China's Communist Party

Rediff.com14 Dec 2020

The data leak obtained by 'The Australian' newspaper has revealed how the alleged CPC members are employed with some of the world's biggest corporations in the areas of defence, banks and pharmaceutical giants manufacturing coronavirus vaccines.

PM holds meet with teams involved in developing COVID vaccine

PM holds meet with teams involved in developing COVID vaccine

Rediff.com30 Nov 2020

The teams were from Gennova Biopharmaceuticals Ltd Pune, Biological E Ltd Hyderabad and Dr Reddys Laboratories Ltd Hyderabad.

Expert panel grants nod to study on mixing Covaxin, Covishield

Expert panel grants nod to study on mixing Covaxin, Covishield

Rediff.com30 Jul 2021

The panel also recommended giving approval to Bharat Biotech for carrying out a study on interchangeability of its Covaxin and the under-trial adenoviral intranasal vaccine candidate BBV154, but asked the Hyderabad-based firm to remove the word "interchangeability" from the study title and submit a revised protocol for approval.

3 lakh remdesivir to be produced daily in 15 days: Govt

3 lakh remdesivir to be produced daily in 15 days: Govt

Rediff.com18 Apr 2021

The government has also given permission to 20 plants to produce the antiviral drug.

Exports jump 60% in March; falls over 7% in FY21

Exports jump 60% in March; falls over 7% in FY21

Rediff.com15 Apr 2021

The country's exports jumped by 60.29 per cent to $34.45 billion in March even as the outbound shipments contracted by 7.26 per cent during the full 2020-21 fiscal to $290.63 billion. Imports too grew by 53.74 per cent to $48.38 billion in March, but dipped by 18 per cent to $389.18 billion during April-March 2020-21, according to the government data released on Thursday. Trade deficit during March 2021 widened to $13.93 billion from $9.98 billion in March 2020.

India remains an attractive FDI destination

India remains an attractive FDI destination

Rediff.com14 Sep 2021

India remains an attractive destination for foreign direct investments (FDI) on account of healthy prospects of economic growth and its skilled workforce, according to a survey by Deloitte. A large proportion of international business leaders remain confident in India's short- and long-term prospects and are readying plans to make additional and first-time investments in the country, it said on Tuesday. "The survey, which questioned 1,200 business leaders of multinational corporations in the US, UK, Japan and Singapore, found that India remains an attractive destination for investments, scoring highly for its skilled workforce and prospects for economic growth," the survey - India's FDI Opportunity - said.

Crisil ups India Inc's credit outlook to 'positive'

Crisil ups India Inc's credit outlook to 'positive'

Rediff.com18 Aug 2021

Crisil Ratings on Wednesday said a broad-based recovery is on for India Inc currently, and upgraded its credit quality outlook to 'positive' from the earlier 'cautiously optimistic'. The rating agency said the credit ratio, which illustrates the number of upgrades to downgrades, rose to over 2.5 times in the first four months of the fiscal, as compared to 1.33 times in the second half of FY21, it said in a statement. The rating agency said it has also done a study of 43 sectors, excluding the financial sector, accounting for 75 per cent of the overall Rs 36 lakh crore in outstanding debt, which shows that the current recovery is broad-based.

Adani, Goenka could lead the charge at IPL team bidding

Adani, Goenka could lead the charge at IPL team bidding

Rediff.com24 Oct 2021

The BCCI will be expecting the two new IPL franchises to go for Rs 7000 crore to Rs 10,000 crore each at the bidding process which begins in Dubai on Monday.

Covishield booster works against Omicron

Covishield booster works against Omicron

Rediff.com24 Dec 2021

If the vaccine is recommended for use as a booster against Omicron, it may significantly boost the demand for Covishield in India.

Covid Vaccine IP: How Big Pharma lobbied against India

Covid Vaccine IP: How Big Pharma lobbied against India

Rediff.com9 Jun 2021

Communications between the USTR and the world's most powerful pharmaceutical and trade lobbying groups reveal that many raised concerns about India's push to exempt Covid vaccines from intellectual property.

India, US committed to taking on toughest challenges together: Biden after meeting Modi

India, US committed to taking on toughest challenges together: Biden after meeting Modi

Rediff.com25 Sep 2021

India and the US are the world's largest democracies and the two countries are committed to taking on the toughest challenges together, President Joe Biden said after his first-ever in-person meeting with Prime Minister Narendra Modi at the White House.

India may not buy Pfizer, Moderna vaccines

India may not buy Pfizer, Moderna vaccines

Rediff.com23 Sep 2021

Though there is no official word, the sources said the government is not ready to give in to the indemnity demands of the US drug manufacturers against liabilities in case of adverse effects.

Govt accepts Cairn's offer on retro tax

Govt accepts Cairn's offer on retro tax

Rediff.com18 Nov 2021

Moving quickly towards ending a retrospective tax dispute with a firm that gave India its largest oilfield, the government has accepted Cairn Energy PLC's undertakings which would allow for the refund of taxes, sources said. Meeting the requirements of the new legislation that scraps levy of retrospective taxation, the company had earlier this month given required undertakings indemnifying the Indian government against future claims as well as agreeing to drop any legal proceedings anywhere in the world. The government has now accepted this and issued Cairn a so-called Form-II, committing to refund the tax collected to enforce the retrospective tax demand, two sources with direct knowledge of the development said.

Hiring sentiment highest in India, 17% firms keen on freshers: Survey

Hiring sentiment highest in India, 17% firms keen on freshers: Survey

Rediff.com22 Sep 2021

Fresher hiring sentiment is highest in India, with 17 per cent employers keen on recruiting fresh graduates in the July to December 2021 period against 6 per cent globally. According to the Career Outlook Report by TeamLease EdTech, conducted across 18 sectors and 14 cities, the hiring sentiment in the country has registered a 2 percentage point increase over the February-April 2021 period. In terms of sectors, those that have been able to withstand the impact of the pandemic and witnessed a stronger hiring sentiment are information technology (31 per cent), telecommunication (25 per cent) and technology start-ups (25 per cent).

Coronavirus may impact India's Q4 GDP growth

Coronavirus may impact India's Q4 GDP growth

Rediff.com2 Mar 2020

Sectors such as electronics, pharmaceuticals and automobiles can see supply disruptions in value chain, which may lead to a derailment of the domestic economic growth.

India pays Cairn Rs 7,900 cr to settle retro tax dispute

India pays Cairn Rs 7,900 cr to settle retro tax dispute

Rediff.com24 Feb 2022

The Indian government has paid Cairn Energy Plc Rs 7,900 crore to refund taxes it had collected to enforce a retrospective tax demand, ending a seven-year-old dispute that had tarred the country's image as an investment destination. The company, which is now known as Capricorn Energy PLC, in a statement said it has received "net proceeds of $1.06 billion", of which nearly 70 per cent will be returned to the shareholders. The tax department had used a 2012 legislation, which gave it powers to go back 50 years and slap capital gains levies wherever ownership had changed hands overseas but business assets were in India, to seek Rs 10,247 crore in taxes from Cairn.

Pakistan to let fully-vaccinated Sikh pilgrims visit Kartarpur Sahib with strict protocols

Pakistan to let fully-vaccinated Sikh pilgrims visit Kartarpur Sahib with strict protocols

Rediff.com22 Aug 2021

The decision to open Kartarpur shrine was taken by the National Command and Operation Centre (NCOC) on Saturday due to the approaching death anniversary of Sikhism founder Baba Guru Nanak Dev on September 22.

Traders seek Army's help to distribute medicines

Traders seek Army's help to distribute medicines

Rediff.com31 Mar 2020

The situation is severe in North India as most of the logistics operation was manned by migrant labourers from Uttar Pradesh and Bihar. The problem with manpower is not only in courier and delivery services, but also at a shop level.

Tatas, Adani, Ambanis in scramble for super app

Tatas, Adani, Ambanis in scramble for super app

Rediff.com8 Nov 2021

The groups plan to take on well-entrenched players like Amazon, Flipkart, and Paytm by merging their offline businesses with e-commerce initiatives.

Covid vaccines for children likely by Sept: AIIMS chief

Covid vaccines for children likely by Sept: AIIMS chief

Rediff.com24 Jul 2021

The trial is being conducted in three phases by segregating children into categories according to their age. The first trial was started in the age group of 12 to 18 years followed by the age group of 6 to 12. Trials for children between the ages of and 2-6 years are currently undergoing trials.

Consumption funds: Go for a maximum 5-10% exposure, say experts

Consumption funds: Go for a maximum 5-10% exposure, say experts

Rediff.com28 Sep 2021

Consumption is among the most diversified and sought-after themes in Indian equities. Over the past five years, consumption theme funds have given an annualised category average return of 15.17 per cent, according to the data from Value Research. But this theme has been affected by the Covid-19 pandemic, which impacted jobs and livelihood.

From earning Rs 300 to associate general manager

From earning Rs 300 to associate general manager

Rediff.com5 Feb 2020

Rediff reader K Srinivasan, 54 who works as associate general manager, corporate relations at BGS Gleneagles Global Hospitals in Bengaluru shares his story.

8 vaccines, 4 treatments in India's COVID-19 arsenal

8 vaccines, 4 treatments in India's COVID-19 arsenal

Rediff.com28 Dec 2021

The Central Drugs Standard Control Organisation has granted restricted emergency use authorisation to two new vaccines and a drug for COVID-19, taking the number of preventives and treatments available in India to 12.

Production of 1 bn vax doses in India on track: Biden

Production of 1 bn vax doses in India on track: Biden

Rediff.com23 Sep 2021

The Quad partnership is on track to produce at least a billion vaccine doses in India by 2022, US President Joe Biden said on Wednesday, asserting that nothing is more urgent than working together to defeat COVID-19 so the world is much better prepared for future pandemics.

PE/VC investments in pharma cos cross $1 bn mark

PE/VC investments in pharma cos cross $1 bn mark

Rediff.com6 Oct 2020

Fund managers said investors remained positive on the pharma manufacturing activity in India, which further strengthened during the Covid-19 period, on account of restrictions imposed on pharma imports from China.

Mumbai still home to most of India's richest

Mumbai still home to most of India's richest

Rediff.com2 Oct 2018

Pharmaceuticals, along with software and services, also added the most new entrants on the rich list 2018.

Johnson & Johnson's single-dose COVID vaccine gets approval in India

Johnson & Johnson's single-dose COVID vaccine gets approval in India

Rediff.com7 Aug 2021

"India expands its vaccine basket! Johnson and Johnson's single-dose COVID-19 vaccine is given approval for Emergency Use in India. Now India has 5 EUA vaccines. This will further boost our nation's collective fight against COVID-19," tweeted the minister.

Why prices of vitamin C, antibiotics could shoot up

Why prices of vitamin C, antibiotics could shoot up

Rediff.com14 Dec 2019

The government said that "in exercise of extraordinary powers in public interest, conferred by paragraph 19 of the DPCO, 2013", the ceiling prices of 21 key formulations had been increased. These formulations include common medicines like BCG vaccines, penicillin, malaria and leprosy medicines (Dapsone), life-saving drugs like Furosemide (used to treat fluid build-up due to heart failure, liver scarring, or kidney disease), vitamin C, some common antibiotics, and anti-allergy medicines.

As domestic sales decline, drug makers focus on exports

As domestic sales decline, drug makers focus on exports

Rediff.com1 Oct 2020

While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.

Beware! New COVID-19 variant with high spike mutations detected in South Africa

Beware! New COVID-19 variant with high spike mutations detected in South Africa

Rediff.com25 Nov 2021

The South African authorities said the detected cases and percentage of people testing positive are both increasing quickly, particularly in particularly in most populated province of Gauteng, North West and Limpopo regions of the country.

Lupin sells Japan arm to Unison for Rs 3,702 cr

Lupin sells Japan arm to Unison for Rs 3,702 cr

Rediff.com12 Nov 2019

The company will now focus on specialty products in Japan; it is open to inorganic opportunities, especially in India.

Cabinet nod for trade pact with Mauritius covering 310 items

Cabinet nod for trade pact with Mauritius covering 310 items

Rediff.com17 Feb 2021

The Union Cabinet on Wednesday approved the signing of a comprehensive economic cooperation agreement, a kind of a free trade pact, between India and Mauritius which is aimed at liberalising norms to boost two-way commerce

Indian pharma exports report double-digit growth after 3 yrs

Indian pharma exports report double-digit growth after 3 yrs

Rediff.com3 May 2019

The only category of pharmaceuticals that showed a negative growth in exports this time was herbal products, exports of which stood at $299 million as compared to $ 312 million in the previous year.

Oxford/AstraZeneca COVID-19 vaccine approved by UK regulator

Oxford/AstraZeneca COVID-19 vaccine approved by UK regulator

Rediff.com30 Dec 2020

The UK's National Health Service was already lining up thousands of medics and volunteers to be ready to deliver jabs up and down the country.

Help people, take their feedback: PM to Union ministers

Help people, take their feedback: PM to Union ministers

Rediff.com30 Apr 2021

Sources said the pandemic and the response of the government is likely to be discussed in the virtual meet.

Regulator asks traders to stock 55 ICU drugs

Regulator asks traders to stock 55 ICU drugs

Rediff.com18 Apr 2020

This is apart from the requirement to stock hydroxychloroquine (200 mg) and Azithromycin (500 mg) tablets for patients requiring ICU management, asymptomatic healthcare workers and asymptomatic household contacts of positive cases.

PE/VC investments drop 51% to $4.1 billion as big deals shrink in July

PE/VC investments drop 51% to $4.1 billion as big deals shrink in July

Rediff.com14 Aug 2020

According to the IVCA-EY report, July recorded 10 large deals worth $3.1 billion compared to 13 large deals worth $7.1 billion in July 2019.

'Large-caps, especially with a value bias, are preferable at this stage'

'Large-caps, especially with a value bias, are preferable at this stage'

Rediff.com7 Jan 2022

'If the third wave of Covid infections is as bad as the second one, the market may get very polarised with a preference for blue-chips with low volatility.'

India raises withdrawal of students' visas with US

India raises withdrawal of students' visas with US

Rediff.com8 Jul 2020

It is understood that India's border row with China figured in the talks between Foreign Secretary Harsh Vardhan Shringla and US Under Secretary of State for Political Affairs David Hale though there was no mention of it in the press statements issued by the two sides.

Infra, small-cap, and PSU funds top one-year performance charts

Infra, small-cap, and PSU funds top one-year performance charts

Rediff.com15 Nov 2021

The one-year returns for equity-oriented mutual fund (MFs) schemes have largely mirrored the gains made in the secondary market. However, schemes that invest in infrastructure (infra), small-cap, and public sector undertaking (PSU) banks have emerged standout performers, with gains in excess of 100 per cent in some cases. Of the total 484 equity schemes, 353 have managed to beat the Sensex, reveals the data provided by Value Research. Around 20 have delivered returns in excess of 90 per cent and six schemes have given returns of over 100 per cent in the past one year. The S&P BSE Sensex Total Return Index (TRI) has given returns of 51 per cent in the last one year, ended October 29.